Christopher Kabrhel1, Rachel Rosovsky2, Richard Channick3, Michael R Jaff4, Ido Weinberg4, Thoralf Sundt5, David M Dudzinski6, Josanna Rodriguez-Lopez7, Blair A Parry8, Savanah Harshbarger8, Yuchiao Chang9, Kenneth Rosenfield10. 1. Center for Vascular Emergencies, Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA. Electronic address: ckabrhel@partners.org. 2. Center for Vascular Emergencies, Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 3. Division of Pulmonary and Critical Care, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 4. Fireman Vascular Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 5. Division of Cardiac Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 6. Center for Vascular Emergencies, Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 7. Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 8. Center for Vascular Emergencies, Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 9. Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 10. Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Abstract
BACKGROUND: Integrating newly developed tests and treatments for severe pulmonary embolism (PE) into clinical care requires coordinated multispecialty collaboration. To meet this need, we developed a new paradigm: a multidisciplinary Pulmonary Embolism Response Team (PERT). In this report, we provide the first longitudinal analysis of patients treated by a PERT. METHODS: Our PERT includes specialists in cardiovascular medicine and surgery, emergency medicine, hematology, pulmonary/critical care, and radiology, and is organized as a rapid response team. We prospectively captured clinical, therapeutic, and outcome data at PERT activation and during follow-up periods up to 365 days. We analyzed data collectively, and as five mutually exclusive 6-month periods. We performed Fisher exact tests and regression analysis to test for trend. RESULTS: In 30 months, there were 394 unique PERT activations, 314 (80%) for confirmed PE. PERT activations increased by 16% every 6 months. Most confirmed PEs were submassive (n = 143, 46%) or massive (n = 80, 26%). The PERT treated a relatively large proportion of patients with PE and systemic or catheter-directed thrombolysis (n = 35, 11%), though the most common treatment was anticoagulation alone (n = 215, 69%). Hemorrhagic complications were rare overall, especially among patients treated with catheter-directed thrombolysis. The all-cause 30-day mortality of PERT patients with confirmed PE was 12%. CONCLUSIONS: We report our initial 30-month experience with a novel multidisciplinary PERT that rapidly engages multiple specialists to deliver efficient, organized, and evidence-based care to patients with high-risk PE. The PERT paradigm was rapidly adopted and may become a new standard of care for patients with PE.
BACKGROUND: Integrating newly developed tests and treatments for severe pulmonary embolism (PE) into clinical care requires coordinated multispecialty collaboration. To meet this need, we developed a new paradigm: a multidisciplinary Pulmonary Embolism Response Team (PERT). In this report, we provide the first longitudinal analysis of patients treated by a PERT. METHODS: Our PERT includes specialists in cardiovascular medicine and surgery, emergency medicine, hematology, pulmonary/critical care, and radiology, and is organized as a rapid response team. We prospectively captured clinical, therapeutic, and outcome data at PERT activation and during follow-up periods up to 365 days. We analyzed data collectively, and as five mutually exclusive 6-month periods. We performed Fisher exact tests and regression analysis to test for trend. RESULTS: In 30 months, there were 394 unique PERT activations, 314 (80%) for confirmed PE. PERT activations increased by 16% every 6 months. Most confirmed PEs were submassive (n = 143, 46%) or massive (n = 80, 26%). The PERT treated a relatively large proportion of patients with PE and systemic or catheter-directed thrombolysis (n = 35, 11%), though the most common treatment was anticoagulation alone (n = 215, 69%). Hemorrhagic complications were rare overall, especially among patients treated with catheter-directed thrombolysis. The all-cause 30-day mortality of PERT patients with confirmed PE was 12%. CONCLUSIONS: We report our initial 30-month experience with a novel multidisciplinary PERT that rapidly engages multiple specialists to deliver efficient, organized, and evidence-based care to patients with high-risk PE. The PERT paradigm was rapidly adopted and may become a new standard of care for patients with PE.
Authors: Jamal H Mahar; Ihab Haddadin; Divyajot Sadana; Abishek Gadre; Natalie Evans; Deborah Hornacek; Natalia Fendrikova Mahlay; Marcelo Gomes; Douglas Joseph; Maya Serhal; Michael Zhen-Yu Tong; Seth R Bauer; Michael Militello; Bernard Silver; Mehdi Shishehbor; John R Bartholomew; Gustavo A Heresi Journal: J Thromb Thrombolysis Date: 2018-08 Impact factor: 2.300
Authors: Colin Wright; Ayman Elbadawi; Yu Lin Chen; Dhwani Patel; Justin Mazzillo; Nicole Acquisto; Christine Groth; Joseph Van Galen; Joseph Delehanty; Anthony Pietropaoli; David Trawick; R James White; Pamela Cameron; Igor Gosev; Bryan Barrus; Neil G Kumar; Scott J Cameron Journal: J Thromb Thrombolysis Date: 2019-08 Impact factor: 2.300
Authors: Thomas M Todoran; Jay Giri; Geoffrey D Barnes; Rachel P Rosovsky; Yuchiao Chang; Michael R Jaff; Kenneth Rosenfield; Christopher Kabrhel Journal: J Thromb Thrombolysis Date: 2018-07 Impact factor: 2.300
Authors: Ayman Elbadawi; Amgad Mentias; Islam Y Elgendy; Ahmed H Mohamed; Mohammed Hz Syed; Gbolahan O Ogunbayo; Odunayo Olorunfemi; Igor Gosev; Sunil Prasad; Scott J Cameron Journal: Vasc Med Date: 2019-03-05 Impact factor: 3.239
Authors: Bindu Akkanti; Ismael A Salas De Armas; Ayaaz K Sachedina; Jennifer M Sunny; Mahmoud Samy Ahmed; Avaleen Kaur; Kha T Dinh; Rahat Hussain; Sachin Kumar; Sriram Nathan; Marwan Jumean; Manish K Patel; Mehmet H Akay; Jayeshkumar A Patel; Barbi Witz; John Zaki; Igor Banjac; Lisa Janowiak; Igor D Gregoric; Biswajit Kar Journal: J Extra Corpor Technol Date: 2020-09
Authors: Aleksander Araszkiewicz; Marcin Kurzyna; Grzegorz Kopeć; Marek Roik; Szymon Darocha; Arkadiusz Pietrasik; Mateusz Puślecki; Andrzej Biederman; Roman Przybylski; Jakub Stępniewski; Michał Furdal; Tatiana Mularek-Kubzdela; Piotr Pruszczyk; Adam Torbicki Journal: Cardiol J Date: 2019 Impact factor: 2.737